MXPA03007837A - Composiciones para suministrar bisfosfonatos. - Google Patents

Composiciones para suministrar bisfosfonatos.

Info

Publication number
MXPA03007837A
MXPA03007837A MXPA03007837A MXPA03007837A MXPA03007837A MX PA03007837 A MXPA03007837 A MX PA03007837A MX PA03007837 A MXPA03007837 A MX PA03007837A MX PA03007837 A MXPA03007837 A MX PA03007837A MX PA03007837 A MXPA03007837 A MX PA03007837A
Authority
MX
Mexico
Prior art keywords
compositions
bisphosphonates
delivering
delivering bisphosphonates
administration
Prior art date
Application number
MXPA03007837A
Other languages
English (en)
Spanish (es)
Inventor
Maria A P Boyd
Original Assignee
Emisphere Techonologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Techonologies Inc filed Critical Emisphere Techonologies Inc
Publication of MXPA03007837A publication Critical patent/MXPA03007837A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA03007837A 2001-03-01 2002-03-01 Composiciones para suministrar bisfosfonatos. MXPA03007837A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27267601P 2001-03-01 2001-03-01
PCT/US2002/006295 WO2002070438A2 (en) 2001-03-01 2002-03-01 Compositions for delivering bisphosphonates

Publications (1)

Publication Number Publication Date
MXPA03007837A true MXPA03007837A (es) 2004-03-16

Family

ID=23040792

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03007837A MXPA03007837A (es) 2001-03-01 2002-03-01 Composiciones para suministrar bisfosfonatos.

Country Status (13)

Country Link
US (1) US7309698B2 (https=)
EP (1) EP1372667B1 (https=)
JP (1) JP4354698B2 (https=)
KR (1) KR20030083725A (https=)
CN (1) CN1492763B (https=)
AU (1) AU2002254082B2 (https=)
BR (1) BR0207871A (https=)
CA (1) CA2438848C (https=)
MX (1) MXPA03007837A (https=)
NZ (1) NZ527157A (https=)
RU (1) RU2309945C2 (https=)
WO (1) WO2002070438A2 (https=)
ZA (1) ZA200305606B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
US6358504B1 (en) * 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
JP2004521857A (ja) 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
EP1401406A2 (en) * 2001-07-02 2004-03-31 Merrion Research I Limited Delivery of a bioactive material
SK2532004A3 (en) * 2001-12-21 2004-11-03 Procter & Gamble Method for the treatment of bone disorders
CN1332711C (zh) * 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
KR20060058151A (ko) * 2002-05-10 2006-05-29 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
ES2291749T5 (es) * 2002-12-20 2011-07-21 F. Hoffmann-La Roche Ag Formulación de altas dosis de ibandronato.
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
CN102001962B (zh) * 2004-05-06 2013-04-03 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
NZ551196A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
AU2005244985B2 (en) 2004-05-19 2011-09-01 Emisphere Technologies, Inc. Acyclovir formulations
CN1968704B (zh) 2004-05-19 2010-12-08 爱密斯菲尔科技公司 局部用色甘酸制剂
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US9399054B2 (en) * 2004-07-12 2016-07-26 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
CN101014360A (zh) 2004-08-03 2007-08-08 埃米斯菲尔技术公司 抗糖尿病口服胰岛素－双胍组合物
WO2006072070A2 (en) 2004-12-29 2006-07-06 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
WO2006076692A1 (en) 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
EP2316441A1 (en) * 2005-02-17 2011-05-04 Hadasit Medical Research Services And Development Bisphosphonates for treating endometriosis
WO2007011958A2 (en) 2005-07-15 2007-01-25 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
KR101191322B1 (ko) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 증진제를 함유하는 고형 경구용 투여 제형
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US8771712B2 (en) 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
JP5475443B2 (ja) 2006-06-28 2014-04-16 エミスフェアー・テクノロジーズ・インク 硝酸ガリウム製剤
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
ES2841379T3 (es) 2007-03-13 2021-07-08 Jds Therapeutics Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
CN107096012A (zh) * 2008-05-07 2017-08-29 诺和诺德股份有限公司 肽的组合物及其制备方法
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
DK2459176T3 (en) 2009-07-31 2017-12-04 Gruenenthal Gmbh Crystallization process and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2461803B1 (en) 2009-08-03 2018-10-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CA3014308A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
UA41909C2 (uk) * 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
US5523434A (en) * 1995-03-15 1996-06-04 The Procter & Gamble Company Synthesis of bleach activators
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1996038406A1 (en) * 1995-05-31 1996-12-05 Kumiai Chemical Industry Co., Ltd. Phenylalkanamide derivatives and agrohorticultural bactericides
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5776888A (en) * 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
NZ509239A (en) * 1998-07-27 2002-10-25 Emisphere Tech Inc 2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents
MXPA01008611A (es) * 1999-02-26 2003-06-24 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
KR100788970B1 (ko) * 1999-11-05 2007-12-27 에미스페어 테크놀로지스, 인코포레이티드 활성제 전달용 페녹시 카르복시산 화합물 및 조성물
ES2298168T3 (es) * 1999-12-16 2008-05-16 Emisphere Technologies, Inc. Compuestos y composiciones para suministrar agentes activos.
ES2386263T3 (es) 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
WO2002019969A2 (en) 2000-09-06 2002-03-14 Emisphere Technologies Inc. (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents

Also Published As

Publication number Publication date
EP1372667A4 (en) 2007-03-14
EP1372667B1 (en) 2014-10-15
CA2438848A1 (en) 2002-09-12
JP4354698B2 (ja) 2009-10-28
CN1492763B (zh) 2012-05-23
RU2003129165A (ru) 2005-03-27
NZ527157A (en) 2005-04-29
WO2002070438A2 (en) 2002-09-12
KR20030083725A (ko) 2003-10-30
EP1372667A2 (en) 2004-01-02
CN1492763A (zh) 2004-04-28
AU2002254082B2 (en) 2007-05-24
HK1062557A1 (en) 2004-11-12
WO2002070438A3 (en) 2003-04-24
CA2438848C (en) 2011-05-03
US7309698B2 (en) 2007-12-18
US20040147484A1 (en) 2004-07-29
ZA200305606B (en) 2004-08-25
JP2004528303A (ja) 2004-09-16
BR0207871A (pt) 2004-06-22
RU2309945C2 (ru) 2007-11-10

Similar Documents

Publication Publication Date Title
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
AU7315301A (en) Compounds and compositions for delivering active agents
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
MXPA04004567A (es) Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
PL347671A1 (en) Compounds and compositions for delivering active agents
AU2274201A (en) Compounds and compositions for delivering active agents
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
MY129263A (en) Vaccine composition
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
TW200508214A (en) Novel compounds
AU3492100A (en) Oxadiazole compounds and compositions for delivering active agents
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
AU7040501A (en) Polymeric micelle compositions
IL188774A0 (en) Compositions for delivery of drug combinations
PL367682A1 (en) Dolastatin 10 derivatives
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2002015959A3 (en) Compounds and compositions for delivering active agents
EP1420827B8 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
MXPA03005980A (es) Composiciones para administracion nasal de insulina.
GR1004358B (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
WO2002100338A3 (en) Compound and composition for delivering active agents
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.

Legal Events

Date Code Title Description
FG Grant or registration